Avenue Therapeutics Reaches Deal With FDA For Phase 3 Safety Study For IV Tramadol
(RTTNews) - Specialty pharmaceutical company Avenue Therapeutics, Inc. (ATXI) announced Thursday that it has reached final agreement with the U.S. Food and Drug Administration on the Phase 3 safety study protocol and statistical analysis approach, including the primary endpoint, for intravenous (IV) tramadol
Tramadol is in development for the treatment of acute post-operative pain in a medically supervised setting. The final non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.
The study will randomize approximately 300 post bunionectomy patients to IV tramadol or IV morphine for pain relief administered during a 48-hour post-operative period. IV tramadol demonstrated safety and efficacy in this same surgical model in two Phase 3 efficacy trials.
The primary endpoint is a composite of elements indicative of respiratory depression. Avenue believes the study can be completed within 12 months and submitted to the FDA to address the CRL and potentially lead to approval of IV tramadol.
Chicago Business Barometer Surges Back Into Expansionary Territory In September
U.S. Consumer Prices Rise 0.3% In August, Slightly Less Than Expected
U.S. Private Sector Job Growth Exceeds Estimates In September
Canadian Stocks Poised For Gains On Oil, Metals Rally
U.S. GDP Jumps Much More Than Previously Estimated In Q2
U.S. Consumer Prices Rise Slightly Less Than Expected In August
Conagra Brands Q1 Profit Rises, Sales Down; Confirms FY27 View; Shares Drop
